Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Clinical trial NCT05945823 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05945823
Sponsor: Taiho Oncology, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer Esophageal Adenocarcinoma Esophageal Squamous Cell Cancer Siewert Type 1 GEJ Cancer Pancreatic Cancer

Start date: 2023-07-13
Primary completion: 2026-01-28
Enrollment: 53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.